Erythropoietin (EPO) Biomarkers Market: How Clinical Demand Is Shaping Diagnostic Priorities

The erythropoietin (EPO) biomarkers market centers on tools that measure the presence and activity of erythropoietin, a hormone produced in the kidneys that regulates red blood cell production in the bone marrow. According to Polaris Market Research, the global market was valued at USD 665.41 million in 2025 and is projected to reach USD 1,433.15 million by 2034, growing at a CAGR of 8.90% from 2026 to 2034. For diagnostic manufacturers, hospital buyers, and laboratory directors, understanding where clinical demand originates is essential for planning product and service strategies.

What EPO Biomarkers Measure and Why They Matter

EPO biomarkers are widely used in laboratory diagnostics to evaluate anemia, kidney function, and oxygen regulation. Blood-based assays and diagnostic platforms measure circulating erythropoietin levels, helping identify diseases associated with abnormal erythropoiesis and oxygen transport. The market covers biomarker assays, diagnostic kits, laboratory testing technologies, and biomarker analysis systems. It excludes erythropoietin drugs and erythropoiesis stimulating agent (ESA) therapeutics, focusing instead on detection tools.

Demand for endogenous EPO testing is anchored in everyday clinical practice. Endogenous EPO dominated the market by biomarker type in 2025, accounting for over 54% share, due to the emphasis on measuring erythropoietin synthesis in patients with chronic kidney disease and anemia. These measurements also help clinicians assess red blood cell synthesis and hypoxia-related physiological responses.

Chronic Kidney Disease as the Core Application

By application, chronic kidney disease diagnosis accounted for the largest share in 2025, at around 48%, owing to the prevalence of anemia in patients with chronic kidney disease. Chronic kidney disease impairs the kidneys’ ability to produce erythropoietin, leading to anemia and decreased red blood cell production. Physicians use erythropoietin biomarker testing to assess the severity of anemia and the erythropoiesis response. The report also cites World Kidney Day, which states that 10% of the world’s population suffers from chronic kidney disease.

Oncology Supportive Care Gains Momentum

Oncology supportive care is projected to grow at the fastest CAGR during the forecast period. A rising number of cancer patients undergoing chemotherapy is increasing treatment-related anemia, as chemotherapy often affects bone marrow function and red blood cell production. Clinical laboratories use erythropoietin biomarker testing to track the progression of anemia and develop supportive care strategies, and biomarker monitoring helps determine treatment plans and patient outcomes.

Technology Platforms Behind Reliable Detection

On the technology side, the immunoassays segment held the largest share in 2025, at approximately 61%, because of the sensitivity and specificity of immunoassay-based detection in blood samples. Immunoassay platforms also offer automation for clinical laboratories.

Chemiluminescent immunoassays are expected to exhibit a robust CAGR during the forecast period, supported by increased analytical sensitivity and diagnostic turnaround. These platforms offer high throughput for large testing volumes, and the growing adoption of automated diagnostic analyzers in hospitals supports segment expansion.

Regional and End-User Dynamics

North America dominated the market in 2025, with over 39% share, supported by advanced diagnostic infrastructure across the US and Canada, a high prevalence of chronic kidney disease, and strong biomedical research activity. Europe accounted for the second largest share. Asia Pacific is projected to grow at the fastest CAGR, helped by rising healthcare expenditure across China, India, and Japan and an increasing chronic kidney disease burden. Among end users, hospitals held the highest share in 2025, at nearly 57%, reflecting increasing diagnostic testing for anemia, kidney diseases, and cancer supportive care.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/erythropoietin-epo-biomarkers-market 

Key Players in the Competitive Landscape

The competitive landscape is influenced by ongoing innovation in detecting erythropoietin and related biomarkers. Key players include Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd., Abbott Laboratories, Siemens Healthineers AG, Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Danaher Corporation, DiaSorin S.p.A., QuidelOrtho Corporation, Randox Laboratories Ltd., Becton, Dickinson and Company, and Sysmex Corporation. Strategic partnerships between diagnostic companies, research centers, and pharmaceutical companies are promoting wider use of biomarker testing.

Conclusion

The Erythropoietin (EPO) Biomarkers Market is developing alongside growing interest in biomarkers for disease assessment, clinical research, and treatment monitoring. EPO-related measurements can support investigations into anemia, kidney disorders, oxygen regulation, and certain hematological conditions. Advances in laboratory testing and diagnostic technologies are creating opportunities to improve analytical accuracy and clinical interpretation. However, variability in testing methods, validation requirements, and the complexity of interpreting biomarker results remain challenges. Collaboration among diagnostic companies, research institutions, and healthcare providers may support innovation. Future market development will depend on expanding clinical applications and stronger evidence supporting the utility of EPO biomarkers.

More Trending Latest Reports By Polaris Market Research:

Private 5G Network Market

North America Robot Operating System Market

Meningitis Diagnosis and Treatment Market

Cell & Gene Therapy Bioanalytical Testing Services Market

North America Robot Operating System Market

Platelet Rich Plasma (PRP) Market

Spare Parts Logistics Market

Water Scale Removal Market: A Way to Lessen the Negative Effects of Hard Water

Carbon Credit Market